<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643719</url>
  </required_header>
  <id_info>
    <org_study_id>14-01981</org_study_id>
    <nct_id>NCT02643719</nct_id>
  </id_info>
  <brief_title>Migraine Treatment in ED</brief_title>
  <official_title>Evaluation of a Behavioral Program for Migraineurs in the Emergency Department.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized pilot feasibility study evaluating the impact of introducing behavioral treatment
      for migraine in the Emergency Department (ED) and prescribing migraine preventive medications
      in the ED. The study will examine the effect of these treatments, both individually and in
      combination, on pain severity and headache-related disability. This study is designed to
      examine the feasibility of comparing four interventions for ED patients presenting with
      migraine. Group 1: Starting topiramate; Group 2: Doing a brief behavioral intervention; Group
      3: Treating with combination therapy of topiramate and behavioral intervention; and Group 4:
      Standard of Care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Verbal numeric rating scale (VNRS) scores</measure>
    <time_frame>24 hours, 72 hours</time_frame>
    <description>To examine whether there is a significant pain reduction for patients in the ED after behavioral therapy, investigators will analyze pain scores in the ED, and at 24 hours and 72 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Headache Impact Test (HIT) scores</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Behavioral intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>topiramate and behavioral intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Relaxation Therapy</intervention_name>
    <description>Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.</description>
    <arm_group_label>Behavioral intervention</arm_group_label>
    <arm_group_label>topiramate and behavioral intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Preventive medication prescriptions given to the patient along with written instructions and information about side effects:
Topiramate 25mg tabs (with a plan to increase to 100mg)</description>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_label>topiramate and behavioral intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abortive Medication (Naproxen and Sumatriptan)</intervention_name>
    <description>All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)</description>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_label>Behavioral intervention</arm_group_label>
    <arm_group_label>topiramate and behavioral intervention</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years to 65 years of age

          -  primary diagnosis of migraine based on the International Classification of headache
             disorders 3 beta criteria

          -  having a migraine 3 or more days/month.

        Exclusion Criteria:

          -  Cognitive Behavioral Therapy (CBT), biofeedback or other relaxation therapy in the
             past year

          -  being on medication used for migraine prevention (topiramate, propranolol, valproic
             acid, amitriptyline/nortriptyline/imipramine/desipramine, botulinum toxin, a SNRI,
             angiotensin-converting enzyme inhibitors (ACE-I) or ARB)

          -  cognitive deficit or other physical problem with the potential to interfere with
             behavioral therapy

          -  substance or alcohol abuse as determined by self-report or prior documentation in the
             medical record.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mia Minen</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ada Rubin</last_name>
    <email>rubina07@nyumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liliana Serrano</last_name>
    <email>Liliana.Serrano2@nyumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mia T Minen, MD, MPH</last_name>
      <email>Mia.Minen@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Mia Ninen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>topiramate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

